Motional Selects Ambarella CVflow® AI Vision Processors for its Driverless Vehicles
2.3.2021 13:00:00 EET | Business Wire | Press release
Ambarella, Inc. (Nasdaq: AMBA), an AI vision silicon company, today announced that Motional, a global leader in driverless technology, has selected Ambarella’s CVflow® family of AI processors for its driverless vehicles. The processors work with Motional’s network of LiDAR, camera, and radar sensors to enable the vehicles’ safe operation in diverse and challenging road conditions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210302005107/en/
Ambarella’s CVflow system on chips (SoCs) will be part of the central processing module in Motional’s driverless vehicles, providing image and computer vision processing for cameras in the sensing suite, including the front-facing cameras. The CVflow AI engine will enable Motional AI algorithms to perform complex computer vision tasks, such as object detection, classification, and image segmentation, with industry-leading power efficiency. Ambarella’s advanced image processing will allow the vehicles to operate in challenging lighting conditions, including low-light and high-contrast situations. The SoC’s H.264 encoding will enable the efficient logging of video data from all cameras in the vehicle.
Motional is leading the industry in making driverless vehicles a reality; the company recently became among the first in the world to put driverless vehicles on public roads, and announced a landmark agreement with Lyft for the largest deployment of robotaxis on a major rideshare network. At the heart of these milestones is Motional’s relentless commitment to safety. The company’s driving record includes navigating more than 1.5 million miles in diverse environments, and providing more than 100,000 public rides with zero at-fault incidents. It has also led the establishment of industry-leading safety standards, having co-published the Safety First for Automated Driving white paper.
“We’re at the forefront of commercializing robotaxis, and it’s critical that our vehicle architecture allows us to scale, while maintaining the highest possible safety standards,” said Joaquín Nuño-Whelan, vice president of hardware, Motional. “Ambarella’s processors provide the AI performance, low power consumption, and advanced image processing necessary for the camera perception to perform well under all conditions. This supports the safe operation of our vehicles as we bring driverless technology to consumers worldwide.”
“We are proud to partner with Motional, a leader in driverless vehicle technology,” said Fermi Wang, CEO of Ambarella. “Motional’s autonomous vehicle expertise, including advanced AI algorithms running on our CVflow SoCs, will enable driverless vehicles that combine safety with exceptional performance.”
Ambarella’s CVflow SoC family offers an open and programmable platform for differentiated high-performance automotive systems. It includes AEC-Q100 qualified processors, as well as processors enabling systems with ISO 26262 ASIL-B (D) functional safety levels. A complete set of tools is provided to accelerate the development and optimization of neural networks, with support for industry-standard training tools including Caffe™, ONNX, PyTorch, and TensorFlow™.
About Ambarella
Ambarella’s products are used in a wide variety of human and computer vision applications, including video security, advanced driver assistance systems (ADAS), electronic mirror, drive recorder, driver/cabin monitoring, autonomous driving, and robotic applications. Ambarella’s low-power system on chips (SoCs) offer high-resolution video compression, advanced image processing, and powerful deep neural network processing to enable intelligent cameras to extract valuable data from high-resolution video streams. For more information, please visit www.ambarella.com
All brand names, product names, or trademarks belong to their respective holders. Ambarella reserves the right to alter product and service offerings, specifications and pricing at any time without notice. © 2021 Ambarella International LP. All rights reserved.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210302005107/en/
Contact information
Ambarella Contact: www.ambarella.com/about/contact/inquiries
Media Contact: Molly McCarthy, Valley Public Relations, mmccarthy@ambarella.com
Investor Relations Contact: Louis Gerhardy, Ambarella, lgerhardy@ambarella.com, (408) 636-2310
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OdysseyRe Announces New Co-Chief Underwriting Officers for EMEA18.5.2026 10:00:00 EEST | Press release
Odyssey Reinsurance Company (OdysseyRe) today announced the appointments of Tegwen Gromellon and Anne-Claire Serres as co-chief underwriting officers of its EMEA division, effective July 1. They succeed longtime Chief Underwriting Officer, Gaël Le Païh, who is retiring later this year following 36 years with the Company. Based in Paris, Serres joined OdysseyRe in 2018 as the market director for France and will lead the division’s business across France, Africa and the Middle East. Gromellon, who joined OdysseyRe in 2004, has served as market director for Germany, Austria, Benelux and Switzerland since 2019. He will take the lead for the rest of Europe, including the relationship with the Company’s representative office in Stockholm for the Nordic markets and across Turkey. “We are delighted to appoint both Tegwen and Anne-Claire to these important leadership positions,” said Isabelle Dubots-Lafitte, chief executive officer of EMEA for OdysseyRe. “These appointments recognize their sign
Prokarium Reports Positive Interim Data from Phase 1/1b PARADIGM-1 trial of ZH9 in NMIBC patients, Demonstrating Excellent Safety and Encouraging Early Efficacy18.5.2026 10:00:00 EEST | Press release
Prokarium, a clinical-stage biopharmaceutical company pioneering bacterial immunotherapies for the treatment of solid tumours, today announced safety and antitumour efficacy results from an interim review of the ongoing Phase 1/1b PARADIGM-1 trial of ZH9 in non-muscle invasive bladder cancer (NMIBC) patients. These data were shared via an oral podium presentation at the American Urology Association (AUA26) Annual Meeting. Prokarium CMO, Dr Josefin-Beate Holz said “These data demonstrate ZH9 as a universally applicable treatment for patients. As the treatment is very well tolerated and is showing impactful outcomes for early and BCG-non-responsive patients alike, it opens up the potential for ZH9 to be a transformative bladder saving treatment.” "There is a clear and urgent need to move beyond BCG. The current treatment burden—requiring up to 18 catheterisations in the first year— detrimentally impacts real-world compliance and patient outcomes," said Ibs Mahmood, CEO of Prokarium. "Pat
Arboris Capital Selects ROYC to Expand Private Markets Capabilities on CapGain Platform18.5.2026 10:00:00 EEST | Press release
Arboris Capital Limited (“Arboris”), a DIFC-based firm arranging alternative investments, authorised by the Dubai Financial Services Authority (DFSA), today announced that it has selected ROYC AB (“ROYC”), a private markets technology and infrastructure provider, to support the continued development of its private markets offering through its platform, CapGain. In its ongoing efforts to expand its private markets capabilities across the Middle East, Arboris has undertaken a strategic review of how to further scale its offering while maintaining the integrity of its existing platform. As a result, Arboris has chosen to integrate ROYC’s fund access, sourcing, and structuring capabilities into CapGain, complementing its existing infrastructure. CapGain is Arboris’s proprietary investment platform, purpose-built to facilitate access between international private market opportunities and Professional Investors in the region. CapGain provides fully digital investor onboarding and KYC, a secu
LogicMonitor and Deutsche Telekom Expand Partnership Across Europe18.5.2026 10:00:00 EEST | Press release
LogicMonitor®, the AI-first platform for Autonomous IT, today announced the expanded availability of its platform within Deutsche Telekom’s managed services portfolio across selected European markets, including DACH, Benelux, and the Nordics. The expansion builds on operational use of LogicMonitor in the United Kingdom since 2023, where it has supported Deutsche Telekom’s service teams in improving visibility across network, cloud, and hybrid infrastructure environments. Experience gained from these deployments is now informing broader service enablement across additional European markets. As enterprise IT environments grow more complex, organisations require more than visibility—they need predictive resilience. Through defined use cases, LogicMonitor complements Deutsche Telekom’s existing service management, monitoring, and security tooling, helping teams anticipate, detect, and resolve issues before they impact business operations. In the United Kingdom, the partnership has delivere
VahatiCor Appoints Harry D. Rowland, Ph.D., as Chief Executive Officer18.5.2026 09:00:00 EEST | Press release
VahatiCor, Inc., a medtech company developing interventional therapies for Coronary Microvascular Dysfunction (CMD), announced today the appointment of Harry D. Rowland, Ph.D., as Chief Executive Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260517830314/en/ VahatiCor CEO, Harry D. Rowland, Ph.D. Rowland previously served as Chief Executive Officer and President of Endotronix, where he led the development and commercialization of the Cordella™ Pulmonary Artery Sensor and Heart Failure System. Under his leadership, Endotronix raised over $150 million and grew to more than 150 employees. He also oversaw the PROACTIVE-HF pivotal trial from execution through FDA premarket approval and commercial launch. Following its acquisition by Edwards Lifesciences in 2024, Rowland stayed on to support key CMS national coverage and CE Mark milestones. "Harry has led a medical company through this arc before. He took Endotronix from
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom